A recent scientific revelation has sparked a fascinating debate: Could a well-known anti-aging compound also be a potential fuel for cancer? Let's dive into this intriguing molecular mystery.
The Double-Edged Sword of Polyamines
Polyamines, naturally occurring molecules found in all living cells, are essential for basic biological functions, particularly cell growth and specialization. Scientists have been intrigued by their potential to promote healthy aging, especially a compound called spermidine, often referred to as a 'geroprotector'.
However, here's where it gets controversial: Polyamines have also been linked to aggressive tumor growth in various cancers. This contrast has left researchers with a burning question: How can a molecule that seems to extend life also contribute to cancer?
Unraveling the Cancer Metabolism Mystery
The connection between polyamines and cancer has been recognized for some time, but the precise mechanisms behind their role in tumor progression have remained elusive. Cancer cells are known to manipulate their metabolism, heavily relying on aerobic glycolysis for rapid energy generation. Yet, the exact influence of polyamines on this metabolic shift has been unclear.
Adding to the complexity is the role of two closely related proteins, eIF5A1 and eIF5A2. While sharing 84% of their amino acid sequence, these proteins exhibit vastly different behaviors. Why do they act so differently? This has been a major unanswered question in the scientific community.
Breaking Down the Molecular Barriers
A team led by Associate Professor Kyohei Higashi from the Faculty of Pharmaceutical Sciences at Tokyo University of Science in Japan set out to investigate. Their study, published in the Journal of Biological Chemistry, Volume 301, Issue 8, provides clarity on how polyamines stimulate cancer cell growth through distinct biological pathways, different from those involved in healthy aging.
Using human cancer cell lines, the researchers examined the impact of polyamines on protein production and metabolism. By reducing polyamine levels with a drug and then restoring them with spermidine, they directly measured polyamines' effect on cancer cells. Through high-resolution proteomic techniques, they analyzed changes across over 6,700 proteins.
Their findings revealed that polyamines primarily boost glycolysis, the process of quickly converting glucose into energy, rather than mitochondrial respiration, which is more closely associated with healthy aging. The team also discovered that polyamines increase levels of eIF5A2 and five ribosomal proteins (RPS 27A, RPL36AL, and RPL22L1), all linked to cancer severity.
The Role of eIF5A1 and eIF5A2
A side-by-side comparison of eIF5A1 and eIF5A2 provided crucial insights. Dr. Higashi explains, "The biological activity of polyamines via eIF5A differs between normal and cancer tissues. In normal tissues, eIF5A1, activated by polyamines, activates mitochondria via autophagy. In cancer tissues, eIF5A2, whose synthesis is promoted by polyamines, controls gene expression at the translational level to facilitate cancer cell proliferation."
In simpler terms, polyamines trigger distinct effects depending on which protein they influence. In healthy cells, they support cellular maintenance and energy production. In cancer cells, they promote rapid growth.
Understanding the eIF5A2 Mechanism
Further experiments revealed how polyamines increase eIF5A2 levels. Typically, the production of eIF5A2 protein is restrained by a small regulatory RNA molecule, miR-6514-5p. Polyamines disrupt this natural brake, allowing for increased production of eIF5A2. The researchers also showed that eIF5A2 controls a unique group of proteins compared to eIF5A1, further emphasizing their separate functions.
Implications for Cancer Treatment and Supplement Safety
These findings have significant implications for cancer treatment and the use of polyamine supplements. They highlight the importance of biological context. In healthy tissues, polyamines may offer anti-aging benefits through eIF5A1. However, in cancerous or pre-malignant tissues, the same molecules can stimulate tumor growth through eIF5A2. This dual behavior explains the challenges in interpreting polyamines' role in medical research.
The study also identifies a potential new therapeutic target. Dr. Higashi remarks, "Our findings reveal an important role for eIF5A2, regulated by polyamines and miR-6514-5p, in cancer cell proliferation. This suggests that the interaction between eIF5A2 and ribosomes, which regulates cancer progression, is a selective target for cancer treatment." Targeting eIF5A2 specifically could theoretically slow cancer growth without interfering with the beneficial effects associated with eIF5A1.
This research represents a significant step forward in understanding the complex and sometimes contradictory roles of polyamines. In the future, scientists may be able to develop strategies that preserve polyamines' positive effects on healthy aging while minimizing their potential to support cancer development.
This study was supported by a Grant-in-Aid for Scientific Research (C) (No. 18K06652) from the Japan Society for the Promotion of Science, the Hamaguchi Foundation for the Advancement of Biochemistry, and an Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University, Japan.
